ERCC5基因+25A>G多态性与晚期结直肠癌铂类药物疗效的相关性  

Relationship between ERCC5+25A>G polymorphism and clinical outcome of patients with advanced colorectal cancer treated with platinum-based chemotherapy

作　　者：陈建芳[1] 梁后杰[1] 邹岚[1] 蒋金妍[1] 陈克力[1] 王东[2] 廖玲[2] 

机构地区：[1]第三军医大学西南医院肿瘤中心,重庆400038 [2]第三军医大学大坪医院野战外科研究所肿瘤中心,400042

出　　处：《临床肿瘤学杂志》2011年第1期9-13,共5页Chinese Clinical Oncology

摘　　要：目的探讨切除修复交叉互补基因5(ERCC5)基因单核苷酸多态性与中国汉族晚期结直肠癌患者铂类药物疗效的相关性。方法应用PCR-LDR法检测以奥沙利铂为主化疗的105例晚期结直肠癌患者ERCC5基因位点+25A>G(rs751402)、+202C>T(rs2296147)及+372C>T(rs2296148)的多态性,分析不同基因型与疾病控制率、无进展生存期(PFS)的相关性。结果本研究人群中各多态性位点的基因型分布均符合Hardy-Weinberg平衡。携带+25A等位基因(AA/AG基因型)患者经以奥沙利铂为主化疗的疾病控制率为73.5%,显著高于携带+25GG基因型患者的51.4%(χ2=5.231,P=0.022)。携带+25GG基因型患者的中位PFS为5个月,低于携带+25AG基因型患者的8个月以及+25AA基因型患者的6个月(χ2=6.916,P=0.009)。+202C>T、+372C>T位点多态性与疾病控制率、中位PFS之间均无显著差异。结论晚期结直肠癌ERCC5基因+25A>G单核苷酸多态性与奥沙利铂化疗的临床疗效相关。Objective To study the relationship between single nucleotide polymorphisms （SNP） in the ERCC5 （excision repair cross complementation group 5） gene and clinical outcome of Chinese patients with advanced colorectal cancer treated with oxali- platin-based chemotherapy. Methods Polymorphisms of ＋ 25A 〉 G （ rs751402 ）, ＋ 202C 〉 T （ rs2296147 ） and ＋ 372C 〉 T （rs2296148） in the ERCC5 gene were detected by PCR-LDR （polymerase chain reaction-ligation detection reaction） from 105 advanced coloreetal cancer patients treated with oxaliplatin-based chemotherapy. Statistical analysis was conducted to investigate the asso- ciation between gene polymorphisms and clinical outcome. Results The genotype distribution of each polymorphism was found to be of Hardy-Weinberg equilibrium in the study. The disease control rate of patients with ＋ 25A allele （73.5%） was significantly higher than that of those with ＋ 25GG genotype （X2 = 5. 231, P = 0. 022）. No significant association or trend was found between ＋ 202C 〉 T, ＋ 372C 〉T polymorphism and disease control rate. The median progression free survival （PFS） of patients with the ＋ 25GG genotype （35/95 eases, 5 months） was significantly lower than that ~ff patients with other genotypes （48/95 case, 8 months for ＋ 25AG genotype and 12/95 cases, 6 months for ＋ 25AA genotype, X2 = 6. 916, P = 0. 009）. No significant difference was found between genotypes of ＋ 202C 〉 T or ＋ 372C 〉 T in the study. Conclusion The results suggested that ERCC5 ＋ 25A 〉 G polymorphism may be associated with clinical outcome of oxaliplatin-based chemotherapy in Chinese patients with advanced eoloreetal cancer.

关 键 词：结直肠癌 切除修复交叉互补基因5 化学治疗 基因多态性 

分 类 号：R735.3[医药卫生—肿瘤]